PCOS gets a new name; change seeks to aid faster diagnosis and treatment, Pg12

Key Highlights:

• The Endocrine Society has decided to rename Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
• The name change aims to improve diagnostic accuracy, reduce delays in treatment, and decrease stigma associated with the condition.
• PCOS affects an estimated 170 million women globally during their reproductive years.
• Diagnosis of PCOS is based on the presence of at least two of three criteria: irregular ovulation, high male hormone levels, and polycystic ovaries.

Detailed Insights:

• The term PCOS is considered inaccurate because ovarian cysts are not always present, leading to misdiagnosis and delayed treatment.
• PMOS emphasizes the endocrine and metabolic dysfunctions underlying the condition, providing a more comprehensive understanding.
• The condition's reproductive focus reinforces stigma, especially where fertility is highly valued culturally.
• PCOS is underpinned by endocrine disturbances in insulin, androgens, neuroendocrine, and ovarian hormones, with metabolic, reproductive, and psychological features.

Key Concepts Involved:

• Hyperandrogenism: High levels of male hormones in females, leading to symptoms like excess hair growth and acne.
• Oligo-anovulation: Infrequent or absent ovulation, resulting in irregular or absent menstrual periods.
• Endocrine System: The system of glands that produce and secrete hormones to regulate various bodily functions.